Nehad Soloman, MD

Nehad Soloman, MD; Joy Schechtman, DO; and Robert Levin, MD, share final thoughts and takeaways on the treatment of rheumatoid arthritis in the community setting.

Nehad Soloman, MD; Joy Schechtman, DO; and Robert Levin, MD, review the integration of precision medicine into the management of rheumatoid arthritis.

Nehad Soloman, MD; Joy Schechtman, DO; and Robert Levin, MD, discuss barriers to rheumatoid arthritis (RA) treatment selection such as insurance access.

Drs Nehad Soloman, Joy Schechtman, and Robert Levine share their thoughts on how MSRC test results impact the treatment selection for patients with RA.

Experts in rheumatology review the molecular signature response classifier (MSRC) test for use in guiding RA treatment selection.

Nehad Soloman, MD, leads a discussion about precision medicine in the treatment arsenal for RA.

Nehad Soloman, MD, Joy Schechtman, DO, and Robert Levine, MD, discuss American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) recommendations regarding appropriate timing when changing therapies in managing RA.

Nehad Soloman, MD, provides final thoughts on what rheumatologists can look forward to in 2023 for rheumatic disease management.

An expert in rheumatology highlights challenges faced in the rheumatology workforce and how to optimize addressing these issues going forward.

Dr Nehad Solman reviews the role of clinical pathways and alternative payment models in rheumatology as well as anticipated changes for 2023.

Rheumatology specialists review factors in switching a patient with RA to a different treatment, including timing, efficacy assessment, and barriers.

Nehad Soloman, MD, Joy Schechtman, DO, and Robert Levine, MD, examine potential risks in continuing a patient on an ineffective treatment in RA.

Nehad Soloman, MD, comments on the use of precision medicine and its advantages in the field of rheumatology.

An expert in rheumatology shares updates in clinical research that may shape rheumatic disease care in the future.

Drs Nehad Soloman, Joy Schechtman, and Robert Levine share insights on how to measure treatment efficacy in the management of RA.

Rheumatology experts discuss the potential roadblocks to treatment of RA, such as insurance access.

Dr Nehad Soloman provides insight on recent approvals and upcoming FDA submissions in biosimilars, including for lupus nephritis, and how they may change the course of rheumatic disease management moving forward.

Nehad Soloman, MD, discusses the impact of new biosimilars to become available in the U.S. in 2023 on rheumatic disease management.

Nehad Soloman, MD; Joy Schechtman, DO; and Robert Levine, MD, review how the increase in treatment options for RA has led to a trial-and-error approach to treatment.

Drs Nehad Soloman, Joy Schechtman, and Robert Levine describe the treatment path from conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) to biologic or targeted disease-modifying antirheumatic drugs (b/tsDMARDs) for a typical rheumatoid arthritis (RA) patient.